4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 89 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $367,883 | -22.6% | 21,401 | 0.0% | 0.00% | +50.0% |
| Q4 2022 | $475,316 | -75.9% | 21,401 | -91.3% | 0.00% | -83.3% |
| Q3 2022 | $1,971,000 | +15.2% | 245,123 | 0.0% | 0.01% | -53.8% |
| Q2 2022 | $1,711,000 | -53.8% | 245,123 | 0.0% | 0.03% | -42.2% |
| Q1 2022 | $3,706,000 | -31.1% | 245,123 | 0.0% | 0.04% | -16.7% |
| Q4 2021 | $5,378,000 | -27.5% | 245,123 | -10.9% | 0.05% | +74.2% |
| Q3 2021 | $7,421,000 | +12.0% | 275,123 | 0.0% | 0.03% | -16.2% |
| Q2 2021 | $6,625,000 | -44.7% | 275,123 | -0.4% | 0.04% | -43.1% |
| Q1 2021 | $11,986,000 | +398.6% | 276,294 | +376.4% | 0.06% | +242.1% |
| Q4 2020 | $2,404,000 | – | 58,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
| Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
| BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
| Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
| Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
| Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
| Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
| Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |